| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Efficacy and safety of triple therapy with vonoprazan for Helicobacter pylori eradication: A multicenter, prospective, randomized controlled trial
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Rong-Shuang Han, Jing-Wen Hao, Tong Wang, Zhi Xin, Guang-Xue Fan, Guo-Dong Wang, Miao-Miao Liu, Cheng-Xia Liu, Qiu-Zi Yang, Zheng-Wu Yang, Xiao-Yan Lv, Chao Zhang, Gang Bian, Jing Meng, Zhen-Qin Cui, Xiao-Jing Yun, Jian-Hua Cao, Shu-Hui Li, Jia-Feng Fan, Hong-Gang Ma, Feng-Yu Gao, Tao Mao, Zi-Bin Tian, Xiao-Hui Song and Ya-Nan Yu |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Qilu Health Outstanding Young Talent Cultivation Project |
QDFY-3839 |
|
| Corresponding Author |
Ya-Nan Yu, MD, Professor, Department of Gastroenterology, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao 266000, Shandong Province, China. yananyu@qdu.edu.cn |
| Key Words |
Helicobacter pylori; Vonoprazan triple therapy; Potassium-competitive acid blockers; Eradication rate; First-line therapy |
| Core Tip |
This multicenter randomized controlled trial pioneered a head-to-head comparison of vonoprazan (VPZ)-based triple therapy (VPZ/amoxicillin/clarithromycin) against China’s standard 14-day bismuth quadruple regimen esomeprazole/bismuth/amoxicillin/clarithromycin (EBAC), while evaluating a novel 10-day VPZ regimen. Among 524 treatment-naïve patients, VPZ triple therapy demonstrated superior eradication rates vs EBAC in intention-to-treat and per-protocol analyses, achieving noninferiority thresholds. Adverse event incidence remained comparable, with the 10-day regimen showing the lowest rate. These findings establish VPZ triple therapy as an effective bismuth-free alternative, validating abbreviated 10-day regimens to enhance compliance without compromising efficacy. |
| Citation |
<p>Han RS, Hao JW, Wang T, Xin Z, Fan GX, Wang GD, Liu MM, Liu CX, Yang QZ, Yang ZW, Lv XY, Zhang C, Bian G, Meng J, Cui ZQ, Yun XJ, Cao JH, Li SH, Fan JF, Ma HG, Gao FY, Mao T, Tian ZB, Song XH, Yu YN. Efficacy and safety of triple therapy with vonoprazan for Helicobacter pylori eradication: A multicenter, prospective, randomized controlled trial. <i>World J Gastroenterol</i> 2025; 31(28): 109001</p> |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
